GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Net Change in Cash

Jafron Biomedical Co (SZSE:300529) Net Change in Cash : ¥-746 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Jafron Biomedical Co's Net Change in Cash for the three months ended in Mar. 2024 was ¥-425 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-746 Mil.

Jafron Biomedical Co Net Change in Cash Historical Data

The historical data trend for Jafron Biomedical Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Net Change in Cash Chart

Jafron Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 190.93 303.32 744.37 211.93 215.20

Jafron Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 535.71 -397.04 23.43 53.09 -425.43

Jafron Biomedical Co Net Change in Cash Calculation

Jafron Biomedical Co's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=916.744+-249.649+-451.911+0.011
=215

Jafron Biomedical Co's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=507.095+-839.268+-93.209+-0.049
=-425

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-746 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jafron Biomedical Co Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Jafron Biomedical Co (SZSE:300529) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Net Change in Cash
Comparable Companies
SHSE:688198 SZSE:300633 SZSE:300298 SHSE:688161 SZSE:002901 SHSE:688617 SZSE:301363 SHSE:688016 SHSE:603658 SHSE:600055 ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085
Website
http://www.jafron.com
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Executives
Li Feng Director
He Xiao Lian Executives
Dong Fan Directors, Directors, and Executives
Ceng Kai Directors, executives
Tang Xian Min Directors, executives
Zhang Ming Yuan Secretary Dong
Fang Li Hua Supervisors
Zhang Guang Hai Directors, executives
Li De Zhi Executives
Lu Shao Zhang Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines